Tangent Medical Named Most Innovative Company for the 2013 Business Excellence Awards
Tangent Medical Named Most Innovative Company for the 2013 Business Excellence Awards
Medical Device Start-Up Named a Winner at National Awards Ceremony Event
ANN ARBOR, MI--(Marketwire - Jan 30, 2013) - Tangent Medical (www.tangentmedical.com), an innovator in IV therapy products and creator of the NovaCath™ Integrated IV Catheter System, has been named the Most Innovative Company at the 2013 Business Excellence Awards announced recently by ActionCOACH, a leading business coaching firm sponsoring the award event.
Acceleron Initiates Phase 2 Study of ACE-536 to Treat Anemia in Patients with Myelodysplastic Syndromes
Acceleron Initiates Phase 2 Study of ACE-536 to Treat Anemia in Patients with Myelodysplastic Syndromes
Acceleron earns $10 million milestone payment from collaboration partner Celgene Corporation
T2 Biosystems Announces Issuance of Patents Covering Components of the T2Dx Direct Detection Device
T2 Biosystems Announces Issuance of Patents Covering Components of the T2Dx Direct Detection Device
LEXINGTON, Mass.--(BUSINESS WIRE)--
.jpg){kind=small}
LS9 Appoints Tjerk de Ruiter as President and Chief Executive Officer
LS9 Appoints Tjerk de Ruiter as President and Chief Executive Officer
SOUTH SAN FRANCISCO, Calif., Jan. 23, 2013 (GLOBE NEWSWIRE) -- LS9, Inc., a technology leader in the development of renewable and sustainable chemicals and fuels, today announced the appointment of Tjerk de Ruiter as President and Chief Executive Officer. Mr. de Ruiter joined LS9 as Chairman of the Board in August 2012 and will maintain that position. Ed Dineen, who has served as CEO of LS9 since December 2010, will remain a member of LS9's board of directors.
Selventa Developing Powerful New Class of Multi-omic Based Diagnostic Test for Autoimmune Disease and Cancer
Selventa Developing Powerful New Class of Multi-omic Based Diagnostic Test for Autoimmune Disease and Cancer
.jpg)
Moderna Appoints Divakar Ramakrishnan, Ph.D., As Senior Vice President Of Process Development, Manufacturing And Quality
Moderna Appoints Divakar Ramakrishnan, Ph.D., As Senior Vice President Of Process Development, Manufacturing And Quality
CAMBRIDGE, Mass., Jan. 16, 2013 /PRNewswire/ -- Moderna Therapeutics, which is developing a new platform designed to spur the body to create its own therapeutic proteins to treat a wide range of diseases, announced today that Divakar Ramakrishnan, Ph.D., is joining the company as Senior Vice President of Process Development, Manufacturing and Quality. His appointment is effective immediately.
BIND Granted 5 US Patents for Medicinal Nanoengineering® Platform & Lead Drug Candidate, BIND-014
BIND Granted 5 US Patents for Medicinal Nanoengineering® Platform & Lead Drug Candidate, BIND-014
Total of Ten U.S. Patents Issued to Company in 2012
BIND and Amgen Sign Development & Commercialization Agreement for Kinase Inhibitor Nanomedicine
BIND and Amgen Sign Development & Commercialization Agreement for Kinase Inhibitor Nanomedicine
BIND Biosciences and Amgen Sign Agreement for the Worldwide Development and Commercialization of a Kinase Inhibitor Nanomedicine
Collaboration to Develop a Novel and Targeted Accurin™ Based on BIND’s Nanomedicine Platform and Amgen’s Kinase Inhibitor
Receptos Doses First Patient in Phase 2 Trial for RPC1063 in Ulcerative Colitis
Receptos Doses First Patient in Phase 2 Trial for RPC1063 in Ulcerative Colitis
SAN DIEGO, Jan. 4, 2013 /PRNewswire/ -- Receptos, Inc., announced today that its selective sphingosine-1- phosphate 1 receptor (S1P1R) modulator, RPC1063, has been administered to the first patient in a Phase 2 study examining the clinical efficacy and safety of induction therapy in patients with moderately to severely active ulcerative colitis (UC).
